This meta-analysis assessed the efficacy and safety of a novel intervention for asthma, bronchial thermoplasty (BT), in patients with moderate-to-severe persistent asthma. An electronic literature search identified three randomized controlled trials (RCT) of BT that recruited 421 patients in total. Outcomes of interest were the Asthma Quality of Life Questionnaire (AQLQ) score, morning peak expiratory flow (PEF), tolerability and safety. Compared with standard medications and sham BT treatment, BT significantly improved AQLQ scores and PEF from baseline to the end of the trials. There were more respiratory adverse events and hospitalizations for adverse respiratory events with BT than with medications or sham treatment during the treatment period, but most events resolved, on average, within a week. This effect of BT treatment was not seen during the posttreatment period. Additional long-term RCT are required to confirm whether BT provides benefit to patients with moderateto-severe persistent asthma.
Introduction
In cases of moderate-to-severe persistent asthma, combination treatment with inhaled corticosteroids (ICS) and a longacting β 2 -agonist (LABA) is one recommended treatment option. 1 Although this approach is generally successful at controlling the symptoms of asthma, a small but substantial number of patients continues to experience symptoms, which represents a management challenge. 1 -4 More specifically targeted treatments that are effective and also reduce the need for medication are required for patients with persistent asthma.
Bronchial thermoplasty (BT) is an innovative procedure: controlled radiofrequency-generated heat is delivered via a catheter inserted in the bronchial tree through a flexible bronchoscope to reduce bronchial smooth muscle mass, contractility and the bronchoconstrictor response in asthma. 5, 6 An increasing amount of evidence suggests that BT may be a potential treatment for asthma, 7 -9 but information Q Wu, Y Xing, X Zhou et al. Bronchial thermoplasty for persistent asthma about the response to BT in asthma patients remains scarce and largely unknown. Thus, the present systematic review was carried out, along with a meta-analysis of the currently available randomized controlled trials (RCT), to evaluate the efficacy and safety of BT in the treatment of patients with moderate-to-severe persistent asthma, with the aim of improving the understanding of this novel asthma intervention. A methodological discussion of the assessment of BT is also provided, and future research priorities in this field are suggested.
Materials and methods

SEARCH STRATEGY
The methods used in this study followed those of the Cochrane Collaboration. 10 A comprehensive search of the current literature was performed, including the Cochrane Library, ClinicalTrials.gov, MEDLINE ® , EMBASE ® , Ovid, and PubMed, to identify RCT of BT in patients with asthma published between January 2000 and June 2010. The search terms included 'bronchial thermoplasty', or 'thermoplasty' and 'bronchial asthma', or 'asthma'. Trials were not excluded on the basis of language. Data quoted as unpublished or derived from abstracts were not used. Two reviewers (Q.W. and X.Z.) independently identified relevant trials and assessed these articles based on the inclusion criteria. Consensus about the trials selected for inclusion in this meta-analysis was reached by discussion between these two researchers.
INCLUSION CRITERIA
The following criteria were used to select RCT for inclusion in the meta-analysis. (i) Target population: patients aged 18 -65 years with moderate-to-severe persistent asthma, defined according to the guidelines of the Global Initiative for Asthma, 11 requiring daily therapy with ICS equivalent to a dose of ≥ 200 µg of beclomethasone and LABA, at a dose of ≥ 100 µg of salmeterol or the equivalent.
(ii) Intervention: all patients received regular maintenance medications of inhaled LABA, ICS or the equivalent. BT group patients underwent three procedures at least 3 weeks apart, 12, 13 performed by delivering radiofrequency energy to the airway using the Alair system. 7, 14 Sham-treated control group patients underwent three sham bronchoscopy procedures, each separated by at least 3 weeks. 13 Evaluations were performed after withdrawal from LABA. (iii) Methodological criteria: studies that followed patients for 52 weeks after randomization were included; comparative studies (historical and non-randomized) and case reports were excluded.
CRITICAL APPRAISAL
Clinical trials were appraised by internal and external validity assessment using a checklist of factors by questionnaire, 10, 15 including the method of allocation and concealment of the randomization schedule, blinding of carers, outcome assessors, followup, method of analysis and results obtained. The quality of RCT reporting was assessed using the Jadad scale. 16, 17 A Jadad scale score < 3 was considered to indicate a low-quality trial. 18, 19 Methodological information for the assessment of validity was extracted by two reviewers (Y.X. and D.W.).
DATA EXTRACTION AND STATISTICAL ANALYSES
Two reviewers (Q.W. and X.Z.) independently extracted data. Intention-to-treat (ITT) results were used whenever available. The outcome of primary interest was the scores on the Asthma Quality of Life Questionnaire (AQLQ); 20 secondary outcomes were Q Wu, Y Xing, X Zhou et al. Bronchial thermoplasty for persistent asthma morning peak expiratory flow (PEF), adverse events and hospitalizations. A meta-analysis was conducted to quantify the efficacy and safety of BT using Review Manager, version 5.0.24 (The Nordic Cochrane Centre, The Cochrane Collaboration 2008, Copenhagen, Denmark) for all statistical analyses.
Trial heterogeneity was estimated using the Cochrane Q statistic. The I 2 statistic, which is the proportion of total variation among studies that is likely to be explained by between-study heterogeneity rather than chance, 21 is reported. When the hypothesis of homogeneity was not rejected, a fixed-effects model was used to calculate summary relative risk (RR), weighted mean difference (WMD) and 95% confidence intervals (CI). Otherwise, a random-effects model with inverse variance weighting was used. 22, 23 For each outcome, trials were pooled within categories of the control group (medications or sham). The number-needed-to-treat (NNT) and the number-needed-to-harm (NNH) were calculated from the pooled RR, 95% CI and cumulative incidences in the control groups using Visual Rx, version 3.0 (Dr Chris Cates' EBM Web Site; available at: http://www.nntonline.net). Begg's rank correlation test and Egger's test were used to assess publication bias statistically. A P-value < 0.05 was considered to be indicative of statistically significant publication bias.
A parallel trial 13 provided the SD for mean morning PEF at baseline and at the end of the study for BT and control groups. The SD for the net change within the BT group and within the control group were calculated by using the following equations, using the method of Follmann et al.: 24 where r is the within-patient correlation between the baseline and the end of study, which is estimated to be 0.5.
Results
STUDY INCLUSION
Three studies meeting the inclusion criteria were selected ( Fig. 1 ) and the characteristics of these studies are presented in Table  1 . 12, 13, 25 A total of 421 patients (ITT) were recruited; the largest study included 288 patients, and the smallest included 32 patients. Two of the trials compared BT with standard asthma medications, 12, 25 and one compared BT with sham BT treatment plus standard asthma medications. 13 One trial scored five out of five for methodological quality, 13 and the other two scored three out of five. 12, 25 All three trials were of high quality and had the same follow-up duration of 52 weeks.
EFFICACY
Improvements in AQLQ scores
The three studies assessed the treatment effect by measuring the change in the AQLQ scores from baseline. 12, 13, 25 Meta-analysis of the two trials 12,25 that compared BT with maintenance medication suggested that the mean improvements in the AQLQ scores from baseline to the end of the trials were greater with BT than with maintenance medication (WMD 0.86; 95% CI 0.47, 1.25) ( Fig. 2 , Table 2 ). There was statistical homogeneity within the medication-control groups and the difference between the treatment groups was statistically significant (P < 0.0001). Only one available trial compared BT with sham BT treatment using AQLQ scores as the outcome measure. 13 The trials were statistically heterogeneous across categories of control groups (P = 0.007, I 2 = 80%), but this single trial showed that the improvement from baseline in the AQLQ score was superior in the BT-treated group SE 13 A larger proportion of BT patients compared with the sham-treated group patients (79% versus 64%, respectively) experienced a clinically meaningful within-patient improvement in AQLQ score of ≥ 0.5. The results were consistent when comparing BT with either control, so a random-effects model was used and summary estimates were calculated and showed that, compared with either control, BT significantly improved the AQLQ scores (WMD 0.63; 95% CI 0.10, 1.15; P = 0.02) ( Fig.  2 , Table 3 ). For the primary endpoint of the AQLQ scores, Begg's rank correlation analysis revealed P = 0.15 and the Egger test revealed P = 0.06.
Improvements in the morning PEF
Pooling data from the three studies 12, 13, 25 showed that the mean improvements in the morning PEF from baseline to the end of the trial were greater with BT than with medications or sham BT treatment (WMD 21.78 l/min; 95% CI 8.06, 35.50) ( Fig. 3 , Table 3 ) and the difference between the groups was statistically significant (P = 0.002). The trials were statistically homogeneous across the control groups.
TOLERABILITY AND SAFETY
Adverse respiratory events
During the treatment period (day of first BT treatment session to 6 weeks after the last BT treatment session), there was an increase in respiratory adverse events in the BT groups (total number of events/total number of OCS, oral corticosteroids; ICS, inhaled corticosteroids; PEF, peak expiratory flow; FEV 1 , forced expiratory volume in 1 s; AQLQ, Asthma Quality of Life Questionnaire; LABA, long-acting β 2 -agonist. Bronchial thermoplasty for persistent asthma patients: 1113/257) compared with the control groups (369/164), but there was no increase in adverse events during the posttreatment period (from the end of the BT treatment period to last follow-up visit at 12 months). The most frequently observed respiratory adverse events in the treatment period for BT patients were wheezing, coughing, chest discomfort, dyspnoea, productive cough and discoloured sputum. Most of these adverse events occurred within 1 day of the bronchoscopy procedure and resolved on average within 1 week. There were no patient deaths and no permanent or significant disability/incapacity in any patient in the trials.
Hospitalizations for adverse respiratory events
Meta-analysis of the three trials 12, 13, 25 suggested that, compared with medication or sham BT treatment, during the treatment period the number of hospitalizations for adverse respiratory events increased in patients following BT (RR 3.78; 95% CI 1.39, 10.24: Fig. 4 , Table 3 ). The difference between the groups was statistically significant (P = 0.009). The corresponding NNH for hospitalizations for adverse respiratory events with BT was estimated to be approximately 15 per year (95% CI 5, 106). Meta-analysis of the three trials suggested that there was no statistically significant increase in hospitalizations for adverse respiratory events with BT compared with medications or sham BT treatment during the post-treatment period (RR 1.15; 95% CI 0.47, 2.79 ( Fig. 5 , Table 3 ). The difference between the groups was not statistically significant.
Discussion
Airway smooth muscle (ASM) increase, due both to hypertrophy (increased size of individual cells) and hyperplasia (increased cell division), contributes to the increased thickness of the airway wall in asthma. 26 Airway narrowing is the final common pathway leading to symptoms and physiological changes in asthma, and ASM contraction in response to multiple bronchoconstrictor mediators and neurotransmitters is the predominant mechanism of airway narrowing. 27
FIGURE 2:
Forest plots showing that the mean improvements in the Asthma Quality of Life Questionnaire scores from baseline to the study end, in a meta-analysis of three trials that assessed the efficacy and safety of bronchial thermoplasty (BT), were greater with BT than with medications or sham BT treatment 12, 13, 25 Study or subgroup
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Furthermore, airway inflammation is thought to cause symptoms of asthma directly and indirectly by inducing contraction of the ASM. 28 Thus, ASM cells should be targeted to treat asthma and specific ASM targets should be the focus for the development of new interventions in asthma. 29 Bronchial thermoplasty is a novel intervention for asthma that targets the ASM and results in a prolonged reduction in ASM mass. 30 However, because it is a novel experimental treatment, only three RCT evaluating BT have been published to date. 12, 13, 25 By pooling these data, the present meta-analysis demonstrated that, over a 1year period, BT provided clinically significant and encouraging improvements in patients with moderate-to-severe persistent asthma. 12, 13, 25 The trials included in this review were of good quality with a Jadad score of ≥ 3 and they used almost identical designs with regard to inclusion and exclusion criteria. 12, 13, 25 Also, publication bias of the RCT data was measured using the Egger test and by visual assessment of a funnel plot.
No evident publication bias was observed.
An important goal of asthma management strategies is to improve healthrelated quality of life. 20, 31 The AQLQ is a validated tool for assessing the impact of asthma and evaluating outcomes of various therapies. 32 AQLQ comprises 32 items that report asthma-related symptoms and limitations over the preceding 2 weeks. The response scale is from 1 to 7, with higher scores indicating a better quality of life. 33, 34 Various methods are available to assess airflow limitations, but two methods have gained widespread acceptance for use in patients > 5 years of age. These are spirometry, particularly the measurement of forced expiration volume in 1 s (FEV 1 ) and forced vital capacity, and the PEF measurement. Measuring the variability of airflow limitation is being given increased prominence, as it is important for both asthma diagnosis and assessment of asthma control. 27 The PEF measurement is valuable in asthmatic patients and can be an important aid in both the diagnosis and monitoring of asthma. 27 The present meta-analysis demonstrated a FIGURE 3: Forest plots showing that the mean improvements in the peak expiratory flow from baseline to the end of each study were greater with bronchial thermoplasty (BT) than with medications or sham BT treatment, in three trials included in a metaanalysis of BT treatment 12, 13, 25 Study or subgroup
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Pavord et al. 25 Cox et al. 12 Subtotal [95% CI] Heterogeneity: χ 2 = 0.63, d.f. = 1 (P = 0.43); I 2 = 0% Test for overall effect: Z = 3.37 (P = 0.0008) This meta-analysis also demonstrated that BT yielded greater improvements in PEF than either comparator, and the difference between the treatments was statistically significant. These data confirm the sustainable bronchodilatory effect of BT, in agreement with the results of a previous study. 7 Based on the results of the safety evaluations, BT was generally well tolerated FIGURE 4: Forest plots showing that hospitalizations for adverse respiratory events occurred more frequently following bronchial thermoplasty (BT) than following standard asthma medications or sham BT treatment during the treatment period, in three trials included in a meta-analysis of the safety and efficacy of BT 12, 13, 25 Study or subgroup
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Pavord et al. 25 Cox et al. 12 Subtotal [95% CI] Total events Heterogeneity: χ 2 = 1.06, d.f. = 1 (P = 0.30); I 2 = 6% Test for overall effect: Z = 1.78 (P = 0.07) 100.0 Bronchial thermoplasty for persistent asthma and safe. During the treatment period (day of first BT treatment session to 6 weeks after the last BT treatment session), there were significantly more respiratory adverse events and hospitalizations for adverse respiratory events with BT than with medications or sham BT treatment. However, most of the adverse events occurred within 1 day of the bronchoscopy procedure and resolved, on average, within a week. There were no patient deaths and no permanent or significant disability/incapacity in any patient in the trials. During the posttreatment period (from the end of the BT treatment period to last follow-up visit at 12 months), there was no statistically significant increase in respiratory adverse events and hospitalizations for adverse respiratory events with BT than with medications or sham BT treatment. There were some limitations to the present meta-analysis. First, and most importantly, all three of the trials provided medications (including controllers and relievers) to all patients in both the BT and control groups. Thus, the effects of BT on asthma independent of these co-administered medications is not known. Secondly, this meta-analysis only included three RCT, so the sample size was small and unpublished studies were not included. Combined with a lack of individual patient data and a lack of information for stratified analysis, these factors precluded a sensitive exploration of publication bias and sensitivity or subgroup analyses, which has limited the validity of this review to a certain extent. Thirdly, because this meta-analysis brought together studies that were diverse both clinically and methodologically, heterogeneity occurred in some of the analyses, which was mainly attributable to one trial. 13 The data remained robust following the removal of this trial from the analysis. Finally, the included trials were underpowered to detect some other important outcomes, such as FEV 1 , FEV 1 % predicted, exacerbations, rescue-medication use, and the longer term (> 1 year) efficacy and safety of BT in moderate-to-severe persistent asthma.
BT vs sham
In conclusion, despite its preliminary nature and the limitations described, this meta-analysis clearly demonstrated that, compared with medications or sham BT treatment, BT significantly improved PEF, quality of life, and was generally well tolerated and safe. The increased risk of transient adverse events after BT was outweighed by the benefits of BT that lasted for ≥ 1 year. BT offers clinicians a novel, addon therapy beyond the current use of inhaled ICS and LABA for asthma 6, 13 and appears to have the potential to provide benefit to patients with moderate-to-severe persistent asthma. Additional long-term RCT are required to evaluate further the efficacy and safety of this novel therapy. Future research priorities may include: (i) studies that determine which level of asthma severity would benefit most from BT and evaluate the most suitable airways to provide the safest and most effective treatment; (ii) larger trials comparing BT with sham treatment in a subset of asthma patients without medications (if feasible clinically and ethically); (iii) more trials (e.g. the ongoing RISA Extension Study -Long Term Safety [ClinicalTrials.gov; NCT00401986]; available at: http://clinicaltrials.gov/ct2/ show/NCT00401986) to assess the longer term (> 1 year) efficacy and safety of BT in asthma patients; and (iv) trials evaluating the effects of BT on inflammation and remodelling in the airways of asthma patients.
